$ILMN (Illumina Inc.)

$ILMN {{ '2016-02-02T21:58:31+0000' | timeago}} • Announcement

Life science research company $ILMN reported a decrease in GAAP net income to $104MM or $0.70 per share in 4Q15 compared to $153MM or $1.03 per share in 4Q14 hurt by higher operating expenses. Revenue was $592MM, up 15% from 4Q14 and up 19% on a constant currency basis. Non-GAAP net income was $121MM or $0.81 per share.

$ILMN {{ '2017-09-07T17:16:59+0000' | timeago}} • Announcement

$ILMN filed a new patent infringement suit against Premaitha Health plc in the High Court of Justice, Chancery Division, Patents Court in UK. $ILMN is seeking all available remedies, including damages and injunctive relief. The suit accuses Premaitha's IONA Test of infringing European Patent titled, "Non-invasive Detection of Fetal Genetic Traits."

$ILMN {{ '2017-08-24T14:30:17+0000' | timeago}} • Announcement

$ILMN and Telegraph Hill Partners launched Verogen Inc. Verogen is headquartered in San Diego. It will be the sole provider of the MiSeq FGx Forensic Genomics System, including the MiSeq FGx sequencer, and has global commercial rights to these products. Kirk Malloy will be CEO of Verogen and Cydne Holt will be GM & Chief Scientific Officer.

$ILMN {{ '2017-08-24T14:30:00+0000' | timeago}} • Announcement

$ILMN announced plans with Telegraph Hill Partners, a San Francisco-based venture capital firm, to establish Verogen, Inc. The independent new company has certain exclusive rights to provide $ILMN’s forensic sequencing technology to forensic customers, including for criminal casework and other forensic applications.

$ILMN {{ '2017-08-01T21:54:49+0000' | timeago}} • Infographic

$ILMN Illumina, Inc. AlphaGraphic: Q2 2017 Highlights

$ILMN {{ '2017-05-22T15:06:11+0000' | timeago}} • Announcement

$ILMN appointed Mark Van Oene as Chief Commercial Officer. Van Oene was previously $ILMN's SVP of the Americas region and subsequently named interim Chief Commercial Officer in late 2016. As Chief Commercial Officer, Van Oene will be responsible for world-wide sales, services and marketing at $ILMN. He will report to CEO Francis deSouza.

$ILMN {{ '2017-04-25T22:27:16+0000' | timeago}} • Webcast

$ILMN expects gross margin to be slightly lower in 2Q17 compared to 1Q17. The operating expense growth also is expected to the drive EPS. The company said that it is seeing new customers emerging in China and it remains bullish on the Chinese market opportunities.

$ILMN {{ '2017-04-25T20:37:01+0000' | timeago}} • Announcement

For 2Q17, $ILMN  expects revenue growth of approx. 7% versus a year ago. GAAP earnings per diluted share attributable to company stockholders is expected to be $0.56-0.61 and non-GAAP earnings per diluted share attributable to company stockholders is expected in the range of $0.65-0.70 for 2Q17.

$ILMN {{ '2017-04-25T20:36:13+0000' | timeago}} • Announcement

For FY17, $ILMN expects revenue growth in the range of 10-12%. Additionally, GAAP diluted EPS attributable to company stockholders is expected to be $5.26-5.36 and non-GAAP EPS attributable to company stockholders is expected to be $3.60-3.70 for FY17.

$ILMN {{ '2017-04-25T20:30:02+0000' | timeago}} • Announcement

Life science research company $ILMN's earnings for 1Q17 quadrupled, helped by a pre-tax gain of $453MM resulting from the GRAIL repurchase of shares from $ILMN. Net income jumped 314% to $373MM or $2.52 per share from $90MM or $0.60 per share a year ago. Revenue increased 4.54% to $598MM.

$ILMN {{ '2017-01-31T23:23:11+0000' | timeago}} • Webcast

$ILMN said that Asia Pacific had a significant growth in 4Q16 as revenue increased 29% YoverY, propelled by China which grew approx. 50%. Europe grew 11%, driven in part by year-end spending. Americas revenue declined 4% due to lower high throughput sequencing instrument shipments.

$ILMN {{ '2017-01-31T23:18:17+0000' | timeago}} • Webcast

$ILMN ended 2016 with approx. 35 HiSeq X customers and 37 HiSeq X instruments and backlogs, which are candidates for conversation to NovaSeq.

$ILMN {{ '2017-01-31T21:59:15+0000' | timeago}} • Announcement

For 1Q17, $ILMN expects revenue to be $580-595MM, GAAP diluted EPS attributable to company stockholders to be $0.51-0.56 and non-GAAP diluted EPS attributable to company stockholders to be $0.60-0.65.

$ILMN {{ '2017-01-31T21:58:45+0000' | timeago}} • Announcement

For FY17, $ILMN projects revenue to grow 10-12%, GAAP diluted EPS attributable to company stockholders to be $3.25-3.35 and non-GAAP diluted EPS attributable to company stockholders to be $3.60-3.70.

$ILMN {{ '2017-01-31T21:54:49+0000' | timeago}} • Announcement

$ILMN reported a rise in 4Q16 profit, helped by higher revenues. Net income rose 18.5% YoY to $123.8MM or $0.84 per diluted share. Revenue increased 5% to $619MM. Non-GAAP EPS was $0.85 compared to $0.81 in the prior year quarter.

$ILMN {{ '2017-01-27T16:35:34+0000' | timeago}} • Announcement

$ILMN appointed Caroline Dorsa to its BoD. Given her financial expertise, Dorsa will also participate on the Audit Committee of the Board. Most recently, as EVP and CFO at Public Service Enterprise Group, Dorsa led the finance, business development, and investor relations teams.

$ILMN {{ '2017-01-12T13:31:30+0000' | timeago}} • Announcement

$ILMN and NRGene announced a collaboration to develop new molecular breeding tools for cattle. As a first step, the companies also announced the completion of a high quality genome assembly of the Nellore cattle in conjunction with researchers at the Universidade Estadual Paulista in Brazil.

$IBM {{ '2017-01-09T14:58:32+0000' | timeago}} • Announcement

$IBM Watson Health and $ILMN announced a groundbreaking partnership to expand access to genome data interpretation by integrating Watson for Genomics into $ILMN's BaseSpace Sequence Hub and tumor sequencing process. The collaboration is designed to help standardize and simplify genomic data interpretation.

$ILMN {{ '2017-01-03T17:50:30+0000' | timeago}} • Announcement

$ILMN announced appointment of Garret Hampton, as EVP of Clinical Genomics,  starting Jan. 9, 2017. Garret will be responsible for leading the clinical genomics group, including the reproductive and genetic health and oncology businesses, regulatory, clinical and medical affairs and the Chief Medical Officer's organization.

$ILMN {{ '2016-12-20T15:37:16+0000' | timeago}} • Announcement

$ILMN announced the appointment of Jonathan Seaton as SVP for Corporate & Business Development. He will join the company on January 3, 2017. Mr. Seaton comes to $ILMN from Becton, Dickinson and Company where he was Vice President and Head of Strategy and Business Development for the Life Sciences segment.

$ILMN {{ '2016-12-07T13:36:43+0000' | timeago}} • Webcast

$ILMN said it extended its management team by appointing Sam Samad as SVP and CFO, who will join the company on Jan. 6, 2017.

Recent Transcripts

ACU (Acme United Corp.)
Friday, October 20 2017 - 3:00pm
WOR (Worthington Industries, Inc.)
Wednesday, September 27 2017 - 6:00pm
PSDV (pSivida Corp.)
Monday, September 11 2017 - 8:30pm
AIRI (Air Industries Group)
Wednesday, August 16 2017 - 8:00pm
CVU (CPI Aerostructures Inc.)
Tuesday, August 8 2017 - 12:30pm
PKI (PerkinElmer Inc.)
Thursday, August 3 2017 - 9:00pm
FLDM (Fluidigm Corporation)
Thursday, August 3 2017 - 9:00pm
INTT (inTEST Corp.)
Thursday, August 3 2017 - 9:00pm
PACB (Pacific Biosciences of California, Inc.)
Wednesday, August 2 2017 - 8:30pm
ILMN (Illumina Inc.)
Tuesday, August 1 2017 - 8:30pm
LBY (Libbey Inc.)
Tuesday, August 1 2017 - 3:00pm
XYL (Xylem Inc.)
Tuesday, August 1 2017 - 1:00pm
GNMK (GenMark Diagnostics, Inc.)
Tuesday, August 1 2017 - 12:30pm
SNE (Sony Corporation)
Tuesday, August 1 2017 - 8:15am
QGEN (Qiagen NV)
Friday, July 28 2017 - 1:00pm
MTD (Mettler-Toledo International Inc.)
Thursday, July 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
IART (Integra LifeSciences Holdings Corporation)
Wednesday, July 26 2017 - 12:30pm
TMO (Thermo Fisher Scientific, Inc.)
Wednesday, July 26 2017 - 12:30pm

AlphaGraphics you may like